In 2014, a joint consensus document dealing with the management of antithrombotic therapy
in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or …

Antiplatelet drugs, such as aspirin, P2Y12 antagonists, and glycoprotein (GP) IIb/IIIa
inhibitors, have proved to be successful in reducing the morbidity and mortality associated …

Background Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet
therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary …

Importance Data on P2Y12 inhibitor monotherapy after short-duration dual antiplatelet
therapy (DAPT) in patients undergoing percutaneous coronary intervention are limited …

Background We hypothesised that ticagrelor, in combination with aspirin for 1 month,
followed by ticagrelor alone, improves outcomes after percutaneous coronary intervention …

Background Patients with stable coronary artery disease and diabetes mellitus who have not
had a myocardial infarction or stroke are at high risk for cardiovascular events. Whether …

Aims The aim of this study was to determine the effect of ticagrelor monotherapy on clinically
relevant bleeding and major ischaemic events in relation to clinical presentation with and …

Aims Patients at high bleeding risk (HBR) represent a prevalent subgroup among those
undergoing percutaneous coronary intervention (PCI). Early aspirin discontinuation after a …

In patients with manifestations of cardiovascular disease, acetylsalicylic acid (popularly
known as aspirin) has been the mainstay of treatment for decades owing to its capacity to …

Most patients with atrial fibrillation (AF) and risk factors for stroke require oral anticoagulation
(OAC) to decrease the risk of stroke or systemic embolism. This is now best achieved with …